rs11979775 - SLC29A4

Magnitude 2.2 · 1 study on file

Reported associations

  • A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort) - Unknown journal (n.d.) · Unknown authors · PubMed 32126890

    ABSTRACT: Background: Antipsychotic-induced weight gain is a common and debilitating side effect of antipsychotics. Although genome-wide association studies of antipsychotic-induced weight gain have been performed, few genome-wide loci have been discovered. Moreover, these genome-wide association studies have included a wide variety of antipsychotic compounds. Aims: We aim to gain more insight in the genomic loci affecting antipsychotic-induced weight gain. Given the variable pharmacological properties of antipsychotics, we hypothesized that targeting a single antipsychotic compound would provide new clues about genomic loci affecting antipsychotic-induced weight gain. Methods: All subjects included for this genome-wide association study (n=339) were first-episode schizophrenia spectrum di


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • amisulpride weight gain risk Moderate

    C allele carriers experience significantly greater weight gain with amisulpride treatment; SLC29A4 nucleoside transporter may alter medication metabolism or appetite signaling

    Discuss with prescriber if considering or currently taking amisulpride